NKX2-1 and lung adenocarcinoma: Although organoid-derived subcutaneous tumors do not perfectly mimic the autochthonous BPN model, these data provide additional orthogonal evidence that Cyclin D2 plays a role in the response of NKX2-1-negative lung adenocarcinoma to MAPK inhibition.